source
- Sacituzumab Govitecan-Trastuzumab Combo Shows Low Response in HER2-Positive Metastatic Breast Cancer After T-DXDThe phase 2 SATEEN trial evaluated sacituzumab govitecan combined with trastuzumab in patients with HER2-positive metastatic breast cancer who had progressed on T-DXD. The study enrolled 27 evalua…
- OncLive launches weekly quiz covering recent breast, lung and pancreatic cancer updatesOncLive released its May 8, 2026 weekly news quiz, inviting readers to test their knowledge of recent developments in breast, lung and pancreatic cancers. The quiz highlights several recent oncolo…